This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Polypipe Bursts Onto London Market

LONDON (The Deal) -- British plastic piping manufacturer Polypipe Group plc squirted 120 million shares onto the London market Friday, April 11, with an initial public offering priced at 245 pence a share and an opening market capitalization of 490 million pounds ($819.5 million).

The shares reached a high of 257 pence and managed to stay above water in conditional trading on Friday morning, despite a broad decline on the London market. But by early afternoon, the unlucky timing of floating in the middle of a global selloff began to take its toll as the shares drifted back below 250 pence.

Nevertheless, as a rare industrial stock among the spate of IPOs coming to market in recent months it had a more auspicious start than another private equity-backed stock, Teaneck, N.J.-based Phibro Animal Health Corp., which was due to start trading on Nasdaq this morning. Phibro reportedly priced at $15 per share, below its initial bookbuilding range of $16 to $18 per share. London-listed private equity firm 3i Group plc was expected to sell about 4 million shares in the Phibro offering, in which Bank of America Merrill Lynch, Morgan Stanley and Barclays plc were serving as joint book-running managers. Perella Weinberg is advising Phibro.

Polypipe's shareholders, Cavendish Square Partners LP and company management, made £294 million from the sale of their stock. Cavendish, a fund managed by London firm Caird Capital LLP, cut its stake in Polypipe from 82% to 23% in the IPO and can look forward to raking in a further £29 million and cutting its stake to about 17% if the over-allotment option is fully realized.

Must Read: Australia to Loosen Rules on Chinese Investment

When conditional trading ends and the company is fully admitted to the Main Market of the London Stock Exchange on April 16, Polypipe will have a free float of about 60%.

Cavendish holds the former Bank of Scotland Integrated Finance portfolio and was spun off by Lloyds Banking Group plc in 2010 into a joint venture with Coller Capital Ltd. The integrated finance unit was among the legacy businesses Lloyds was required to sell following its disastrous acquisition of HBOS plc in January 2009. While it included a large number of construction and real estate investments considered to have played a large part in HBOS' collapse, it also held successful companies, including Polypipe. Lloyds still holds 30% of the joint venture, while Coller owns 70%.

When Polypipe announced its intention to float last month, it said it saw its return to the stock market after 14 years as an opportunity to take advantage of the emerging cyclical recovery in the U.K. construction market. The initial H in HBOS stands for Halifax plc, a bank which merged with Bank of Scotland plc in 2001. But Doncaster, England-based Polypipe has no historical connection with the U.S. pipe maker of the same name, despite the coincidence that Polypipe Holdings Inc., of Gainsville Texas, was also owned by a private equity firm called Halifax Group until its sale to Dura-Line Holdings Inc. in 2012.

Polypipe is advised by Mark Aedy and Liam Beere of Moelis & Co. LLC.

Deutsche Bank AG and Numis Securities Ltd. are acting as joint sponsors and joint bookrunners. The Deutsche Bank team includes Lorcan O'Shea, Charles Wilkinson and Simon Gorringe, while Heraclis Economides, Alex Ham and Richard Thomas are representing Numis. Colin Christie and Bruce Garrow of Canaccord Genuity Ltd. are acting as co-lead manager.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $93.64 -0.11%
FB $118.57 0.84%
GOOG $698.21 0.75%
TSLA $241.80 0.43%
YHOO $36.53 -0.19%


Chart of I:DJI
DOW 17,891.16 +117.52 0.66%
S&P 500 2,081.43 +16.13 0.78%
NASDAQ 4,817.5940 +42.2360 0.88%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs